ClinicalTrials.gov term: Hidradenitis
14 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 10 with minor changes only.
Recruitment opened
Also in this update: Trial sites expanded: 12 → 34 locations
Spyre Therapeutics, Inc.Phase 2 NCT07766005 Registry history of NCT07766005 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date pushed from Oct 14, 2026 to Oct 15, 2026; Study completion moved earlier from Jul 17, 2028 to Jan 18, 2028
Novartis PharmaceuticalsPhase 1 NCT07855276 Registry history of NCT07855276 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Corvus Pharmaceuticals, Inc.Phase 1 NCT07828860 Registry history of NCT07828860 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Harrison DermatologyPhase 2 NCT07689188 Registry history of NCT07689188 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 108 participants (planned 96)
Citryll BVPhase 2 NCT06993233 Registry history of NCT06993233 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 11, 2026 to Sep 11, 2026
Novartis PharmaceuticalsPhase 2 NCT03827798 Registry history of NCT03827798 on ClinicalTrials.gov (opens the registry)
Trial completed
Tulane UniversityPhase 2 NCT07077902 Registry history of NCT07077902 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Jun 2026 to Oct 1, 2026
PeriPharmNot specified NCT07323303 Registry history of NCT07323303 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 58 → 64 locations
And 1 more change in the last 30 days
Bluefin Biomedicine, Inc.Phase 2/3 NCT07287644 Registry history of NCT07287644 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 83 → 86 locations
And 1 more change in the last 30 days
SanofiPhase 2 NCT07225569 Registry history of NCT07225569 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 34 → 44 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07665437 Registry history of NCT07665437 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 79 → 85 locations
SanofiPhase 2 NCT07170917 Registry history of NCT07170917 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 15 locations
Also in this update: Start date changed from estimate of Aug 20, 2026 to Aug 21, 2026
Oruka Therapeutics, Inc.Phase 2 NCT07783542 Registry history of NCT07783542 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Nov 2026 to Sep 18, 2026
Zura Bio IncPhase 2 NCT06993610 Registry history of NCT06993610 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-09-21 | NCT07830329 Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe… | Regeneron new | Phase 2 |
| 2026-09-18 | NCT07828860 Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | Corvus Pharmaceuticals, Inc. new | Phase 1 |
| 2026-09-04 | NCT07805798 Urinary Bladder Matrix (UBM) Registry | Integra LifeSciences Corporation new | |
| 2026-09-04 | NCT07804134 Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring… | Medisch Spectrum Twente new | |
| 2026-08-24 | NCT07783542 ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa | Oruka Therapeutics, Inc. new | Phase 2 |
| 2026-08-14 | NCT07766005 A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The… | Spyre Therapeutics, Inc. new | Phase 2 |
| 2026-08-10 | NCT07755670 Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using… | Second Xiangya Hospital of Central South University new |
| Early Phase 1 | 3 | |
| Phase 1 | 10 | |
| Phase 1/2 | 2 | |
| Phase 2 | 23 | |
| Phase 2/3 | 1 | |
| Phase 3 | 13 | |
| Phase 4 | 3 |
Novartis Pharmaceuticals (15) · Incyte Corporation (6) · AbbVie (5) · Peking Union Medical College (4) · Sanofi (4) · Almirall, S.A. (2) · Assistance Publique - Hôpitaux de Paris (2) · MoonLake Immunotherapeutics AG (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Sonoma Biotherapeutics, Inc. (2)